101 |
NCT01926054 |
Recruiting |
ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis |
- SLE Glomerulonephritis Syndrome, WHO Class V
|
|
Interventional |
Phase 4 |
- Ohio State University
- Mallinckrodt
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with adverse events
- Change in laboratory data
- Renal Response to Acthar Gel
- (and 3 more...)
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT01926054 |
2013H0121 |
|
July 2013 |
February 2018 |
|
August 20, 2013 |
January 19, 2017 |
|
- The Ohio State University Wexner Medical Center, Nephrology Clinical Trials Unit
Columbus, Ohio, United States
|
102 |
NCT03334851 |
Recruiting |
Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis |
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
|
- Drug: PF-06835375
- Drug: Placebo
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Number of participants with adverse events (AEs) by seriousness and relationship to treatment
- Number of participants with change from baseline in labboratory test results
- Number of participants with clinically relevant changes from baseline in ECG parameters
- (and 20 more...)
|
112 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03334851 |
C1131001 2017-003077-34 |
|
November 17, 2017 |
November 15, 2021 |
November 15, 2021 |
November 7, 2017 |
March 29, 2018 |
|
- Pinnacle Research Group, LLC
Anniston, Alabama, United States - Pinnacle Research Group, LLC
Anniston, Alabama, United States - Wallace Rheumatic Studies Center
Beverly Hills, California, United States - (and 3 more...)
|
103 |
NCT02270957 |
Recruiting |
Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches |
- Systemic Lupus Erythematosus
|
- Biological: Abatacept
- Other: Placebo
|
Interventional |
Phase 2 |
- Oklahoma Medical Research Foundation
- Bristol-Myers Squibb
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- BILAG-based Combined Lupus Assessment (BICLA)
- BICLA and SRI at each month
- Mean SLEDAI at baseline vs 6 months
- (and 3 more...)
|
60 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02270957 |
OMRF 13-38 |
ABC |
January 2014 |
December 2018 |
December 2019 |
October 22, 2014 |
December 7, 2017 |
|
- Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, United States
|
104 |
NCT01532310 |
Recruiting |
Belimumab (BENLYSTA®) Pregnancy Registry |
- Systemic Lupus Erythematosus
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Birth defects
- Other pregnancy outcomes
- Infant outcomes
|
500 |
Female |
Child, Adult, Senior |
NCT01532310 |
114256 WEUKBRE6076 |
|
July 16, 2012 |
November 26, 2021 |
November 26, 2021 |
February 14, 2012 |
August 9, 2017 |
|
- GSK Investigational Site
Wilmington, North Carolina, United States
|
105 |
NCT02338999 |
Recruiting |
Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE) |
- Systemic Lupus Erthematosus
|
- Radiation: PET/CT
- Drug: Pioglitazone
- Procedure: Vascular function studies
|
Interventional |
Phase 1 Phase 2 |
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Vascular function and inflammation
- Lupus disease activity and immmunomodulation
|
70 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02338999 |
150060 15-AR-0060 |
|
January 14, 2015 |
January 31, 2020 |
January 31, 2020 |
January 15, 2015 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
106 |
NCT02682407 |
Recruiting |
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 |
|
- Biological: OMS721
- Other: Vehicle (D5W)
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety as assessed by the incidence of adverse events up until the last visit at Week 104.
- Assessment of the safety of OMS721 on laboratory measures.
- Assess the effect of OMS721 on proteinuria.
|
44 |
All |
18 Years and older (Adult, Senior) |
NCT02682407 |
OMS721-GNP-001 |
|
February 2016 |
December 2018 |
December 2018 |
February 15, 2016 |
January 16, 2018 |
|
- Omeros Investigational Site
Denver, Colorado, United States - Omeros Investigational Site
Augusta, Georgia, United States - Omeros Investigational Site
Evergreen Park, Illinois, United States - (and 4 more...)
|
107 |
NCT00582881 |
Recruiting |
Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus |
- Mixed Connective Tissue Disease (MCTD)
- Systemic Lupus Erythematosus (SLE)
|
|
Observational |
|
- University of Miami
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Data characterizing immune cell responses and corresponding clinical data
- Phenotype measurement to include disease activity, disease severity, and functional status
|
400 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT00582881 |
20030724 5R01AR043308-16 5R01AR043308-14 |
|
October 2007 |
July 2020 |
July 2020 |
December 28, 2007 |
August 8, 2017 |
|
- University of Miami Miller School of Medicine
Miami, Florida, United States
|
108 |
NCT03098823 |
Recruiting |
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE |
- Lupus Erythematosus, Systemic
- Lupus Erythematosus
- Fatigue
|
- Drug: RAYOS
- Drug: Prednisone
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
62 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT03098823 |
AMP-002 |
RIFLE |
September 12, 2017 |
June 2018 |
June 2018 |
April 4, 2017 |
January 16, 2018 |
|
- Cedars-Sinai Medical Center
Los Angeles, California, United States - The Regents of the University of California, Los Angeles
Los Angeles, California, United States - University of California-Irvine
Orange, California, United States - (and 18 more...)
|
109 |
NCT03370263 |
Recruiting |
BENLYSTA® Special Drug Use Investigation |
- Systemic Lupus Erythematosus
|
|
Observational |
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Change from Baseline in Safety of Estrogens in Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA SLEDAI)
- Change from Baseline in Physician's Global Assessment (PGA) score
- Change from Baseline in Lupus Impact Tracker score
- (and 3 more...)
|
600 |
All |
Child, Adult, Senior |
NCT03370263 |
207735 |
|
January 15, 2018 |
June 26, 2025 |
June 26, 2025 |
December 12, 2017 |
February 12, 2018 |
|
- GSK Investigational Site
Hiroshima, Japan
|
110 |
NCT01180361 |
Recruiting |
Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance |
|
|
Observational |
|
- Winthrop University Hospital
- Arthritis Foundation
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- Comparison of 27-hydroxylase level in THP-1 monocytes incubated in human plasma (RA patient, SLE, normal control, psoriatic arthritis).
- Plasma 27-hydroxycholesterol levels.
|
160 |
All |
18 Years to 65 Years (Adult) |
NCT01180361 |
08310 |
|
September 2008 |
December 2018 |
December 2018 |
August 12, 2010 |
January 29, 2018 |
|
- Winthrop University Hospital
Mineola, New York, United States
|
111 |
NCT03374618 |
Recruiting |
Neutrophil Extracellular Traps in Systemic Sclerosis |
- Systemic Lupus Erythematosus
- Systemic Sclerosis
|
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Quantification of neutrophil extracellular traps (NETs) generated after stimulation of neutrophils in vitro by serum from SSC, SLE and healthy controls.
- Analysis of the composition of neutrophil extracellular traps
- Analysis of the cytokines influencing NETs production in vitro
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT03374618 |
PO17014 |
NET-SSC |
October 6, 2017 |
October 6, 2019 |
October 7, 2019 |
December 15, 2017 |
December 15, 2017 |
|
- Damien JOLLY
Reims, France
|
112 |
NCT03492255 |
Recruiting New |
CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid |
- Systemic Lupus Erythematosus (SLE)
|
- Drug: Cyclophosphamide
- Drug: Methylprednisolone
- Drug: Prednisone
- Drug: Mycophenolate Mofetil
|
Interventional |
Not Applicable |
- University of Sao Paulo General Hospital
- Fundação de Amparo à Pesquisa do Estado de São Paulo
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Partial renal response
- Complete renal response
- Osteoporosis evaluation
- (and 10 more...)
|
232 |
All |
18 Years and older (Adult, Senior) |
NCT03492255 |
CYCLONES |
CYCLONES |
April 12, 2018 |
October 30, 2018 |
December 31, 2022 |
April 10, 2018 |
April 17, 2018 |
|
- Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo
São Paulo, Sao Paulo, Brazil - Hospital das Clinicas da Faculdade de Medicina da USP
São Paulo, Brazil
|
113 |
NCT02444728 |
Recruiting |
Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE |
|
- Drug: Hydroxychloroquine
- Drug: Cyclophosphamide
- Drug: Azathioprine
- Drug: Methylprednisolone
|
Interventional |
Phase 3 |
- Chinese SLE Treatment And Research Group
- Peking Union Medical College Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- complete remission rate
- partial remission rate
|
220 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02444728 |
CSTAR001 |
CHORUS |
July 2015 |
January 2018 |
December 2018 |
May 14, 2015 |
March 9, 2017 |
|
- the Affiliated Hospital to Bangbu Medical University
Bangbu, Anhui, China - Hebei Provincial Hospital
Shijiazhuang, Hebei, China - the First Affiliated Hospital of Xiangya Medical University
Changsha, Hunan, China - (and 12 more...)
|
114 |
NCT02284984 |
Recruiting |
Synergetic B-cell Immodulation in SLE |
- Lupus Erythematosus, Systemic
|
- Drug: Rituximab with belimumab
|
Interventional |
Phase 2 |
- Leiden University Medical Center
- Dutch Kidney Foundation
- ZonMw: The Netherlands Organisation for Health Research and Development
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Reduction of pathogenic autoantibodies
- Seroconversion of pathogenic autoantibodies, in particular anti-dsDNA autoantibodies
- Safety and feasibility: number of patients with (serious) adverse events
- (and 3 more...)
|
15 |
All |
18 Years to 64 Years (Adult) |
NCT02284984 |
NL4813605814 |
SYNBIoSe |
March 2014 |
March 2018 |
March 2020 |
November 6, 2014 |
August 23, 2017 |
|
|
115 |
NCT02525835 |
Not yet recruiting |
Tissue Sodium in Autoimmune Disease |
- Systemic Lupus Erythematosus
|
- Dietary Supplement: Low Dietary Sodium
- Dietary Supplement: High Dietary Sodium
|
Interventional |
Not Applicable |
- Vanderbilt University
- Vanderbilt University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- sodium concentration in skin
- SLEDAI
- blood pressure
|
21 |
All |
18 Years and older (Adult, Senior) |
NCT02525835 |
150713 |
|
December 1, 2018 |
August 2020 |
August 2020 |
August 17, 2015 |
January 25, 2018 |
|
- Vanderbilt University
Nashville, Tennessee, United States
|
116 |
NCT01379573 |
Recruiting |
Preventive Approach to Congenital Heart Block With Hydroxychloroquine |
- Congenital Heart Block
- Neonatal Lupus
- Autoantibody-Associated Heart Block
|
|
Interventional |
Phase 2 |
- New York University School of Medicine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Recurrence of advanced heart block
- Prolonged PR interval (>150msec)
- Any sign of myocardial injury, without change in cardiac rate or rhythm
- (and 6 more...)
|
54 |
Female |
18 Years to 45 Years (Adult) |
NCT01379573 |
11-00369 |
PATCH |
January 2011 |
December 2018 |
December 2018 |
June 23, 2011 |
October 13, 2017 |
|
- New York University School of Medicine
New York, New York, United States
|
117 |
NCT03201406 |
Recruiting |
Retrospective Analysis of Renal Prognosis in Patients With Chronic Kidney Disease |
- Diabetic Nephropathies
- Lupus Nephritis
- Rapidly Progressive Glomerulonephritis
- Chronic Kidney Diseases
|
|
Observational |
|
- National Taiwan University Hospital
|
Other |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- End Stage Renal Disease
- Mortality
|
837 |
All |
20 Years to 100 Years (Adult, Senior) |
NCT03201406 |
201612068RIND |
|
June 20, 2017 |
October 31, 2017 |
December 31, 2017 |
June 28, 2017 |
July 2, 2017 |
|
- National Taiwan University Hospital
Taipei, Taiwan - Yung-Ming Chen
Taipei, Taiwan
|
118 |
NCT02618967 |
Recruiting |
Single Ascending Dose Study of AMG 570 in Healthy Subjects |
- Systemic Lupus Erythematosus
|
- Biological: AMG 570
- Biological: AMG 570 Matching Placebo
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Subject incidences of treatment-emergent adverse events.
- Clinically significant changes in physical examinations.
- Clinically significant changes in vital signs.
- (and 8 more...)
|
56 |
All |
18 Years to 65 Years (Adult) |
NCT02618967 |
20140322 |
|
March 28, 2016 |
August 15, 2018 |
August 15, 2018 |
December 2, 2015 |
April 13, 2018 |
|
- Research Site
Evansville, Indiana, United States - Research Site
Overland Park, Kansas, United States - Research Site
Madison, Wisconsin, United States
|
119 |
NCT01861561 |
Recruiting |
Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children |
- Renal Insufficiency
- Infection
|
- Drug: Low-dose intravenous cyclophosphamide
- Drug: High-dose intravenous cyclophosphamide
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
70 |
All |
up to 15 Years (Child) |
NCT01861561 |
125/2556(EC2) |
Low/highIVCY |
May 2013 |
May 2018 |
November 2018 |
May 23, 2013 |
April 4, 2017 |
|
- Nephrology division, Department of Pediatrics, Siriraj Hospital
Bangkoknoi, Bangkok, Thailand
|
120 |
NCT03122431 |
Recruiting |
Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases |
- Systemic Lupus Erythematosus (SLE)
- Juvenile SLE
- Cutaneous Lupus
|
- Drug: Thalidomide
- Drug: Hydroxychloroquine reduced
- Drug: Hydroxychloroquine high
|
Interventional |
Phase 4 |
- University of Sao Paulo General Hospital
- Fundação de Amparo à Pesquisa do Estado de São Paulo
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Serum levels of thalidomide
- Serum levels of hydroxycloroquine - HCQ reduced
- Serum levels of hydroxycloroquine - HCQ high
|
296 |
All |
5 Years to 64 Years (Child, Adult) |
NCT03122431 |
HPLC-Rheumatic diseases |
|
June 5, 2017 |
June 1, 2020 |
June 5, 2022 |
April 20, 2017 |
April 19, 2018 |
|
- Hospital das Clinicas da Faculdade de Medicina da USP
São Paulo, Brazil
|
121 |
NCT02270970 |
Recruiting |
Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy |
- Systemic Lupus Erythematosus
|
|
Interventional |
Phase 4 |
- Oklahoma Medical Research Foundation
- GlaxoSmithKline
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- BLAST-50 response rate in clinical responders vs non responders
- Time to flare compared to historical (untreated) controls from the BOLD study
- SRI-4 response rates compared to historical controls from the BOLD study
- (and 6 more...)
|
20 |
All |
16 Years to 70 Years (Child, Adult, Senior) |
NCT02270970 |
OMRF 14-18 |
BLAST |
October 2014 |
December 2018 |
December 2019 |
October 22, 2014 |
December 7, 2017 |
|
- Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, United States
|
122 |
NCT03453619 |
Recruiting |
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies |
- IgA Nephropathy
- Lupus Nephritis
- Membranous Nephropathy
- (and 2 more...)
|
|
Interventional |
Phase 2 |
- Apellis Pharmaceuticals, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
48 |
All |
18 Years to 69 Years (Adult, Senior) |
NCT03453619 |
APL2-201 |
|
January 22, 2018 |
July 22, 2019 |
October 22, 2019 |
March 5, 2018 |
April 20, 2018 |
|
- Apellis Investigational Site
Stanford, California, United States - Apellis Investigational Site
Washington, District of Columbia, United States - Apellis Investigational Site
Coral Gables, Florida, United States - (and 7 more...)
|
123 |
NCT00513591 |
Recruiting |
Duke Autoimmunity in Pregnancy Registry |
- Pregnancy
- Systemic Lupus Erythematosus
- Cutaneous Lupus
- (and 3 more...)
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
1000 |
Female |
18 Years and older (Adult, Senior) |
NCT00513591 |
Pro00000756 |
DAP Registry |
August 2007 |
June 2018 |
June 2018 |
August 8, 2007 |
June 16, 2017 |
|
- Duke University Medical Center
Durham, North Carolina, United States
|
124 |
NCT02554474 |
Recruiting |
OPAM-IA: Using Digital Activity Trackers to Improve Physical Activity in Inflammatory Arthritis |
- Joint Diseases
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
|
- Behavioral: Education, Fitbit/FitViz, physiotherapist counselling.
- Behavioral: Same intervention with a 2 month delay
|
Interventional |
Not Applicable |
- University of British Columbia
- Simon Fraser University
- Arthritis Research Centre of Canada
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Time spent in Moderate to Vigorous Physical Activity (MVPA)
- Time spent in sedentary behaviors
- Fatigue Severity Scale
- (and 4 more...)
|
130 |
All |
19 Years and older (Adult, Senior) |
NCT02554474 |
H15-01843 |
|
January 2017 |
April 2019 |
August 2019 |
September 18, 2015 |
April 3, 2018 |
|
- Arthritis Research Canada
Richmond, British Columbia, Canada
|
125 |
NCT02699437 |
Recruiting |
Prevalence of Antiphospholipid Antibodies Among Women With Preeclampsia |
|
- Other: Testing for antiphospholipid antibodies
|
Observational |
|
- Mohamed Sayed Abdelhafez
- Mansoura University
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Rate of positive antiphospholipid antibodies
|
200 |
Female |
20 Years to 35 Years (Adult) |
NCT02699437 |
HME |
|
April 2015 |
August 2017 |
September 2017 |
March 4, 2016 |
May 10, 2017 |
|
- Obstetrics and Gynecology Department in Mansoura University Hospital
Mansoura, Dakahlia, Egypt
|
126 |
NCT03355482 |
Recruiting |
MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE |
- Systemic Lupus Erythematosus Arthritis
|
- Drug: Methylprednisolone
- Drug: Placebos
|
Interventional |
Phase 2 |
- Oklahoma Medical Research Foundation
- Bristol-Myers Squibb
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- combined MRI synovitis, osteitis and tendinitis score at 3 months compared to baseline in clinical responders
|
40 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03355482 |
17-09 BMS IM101-636 |
MEASURE |
April 10, 2017 |
December 2019 |
December 2019 |
November 28, 2017 |
December 7, 2017 |
|
- Access Health
Las Vegas, Nevada, United States
|
127 |
NCT02550964 |
Recruiting |
Incidence and Risk Factor of Hydroxychloroquine and Chloroquine Retinopathy |
|
- Procedure: Composite Examination
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of toxic maculopathy associated with HCQ or CQ
- Risk factor of HCQ/CQ retinopathy
- Characteristics and type of HCQ/CQ retinopathy (parafoveal or pericentral retinopathy)
- Progression of retinopathy after drug cessation
|
124 |
All |
19 Years and older (Adult, Senior) |
NCT02550964 |
2013-0826 |
|
January 2014 |
January 2019 |
January 2019 |
September 16, 2015 |
September 18, 2015 |
|
- Asan Medical Center
Seoul, Korea, Republic of
|
128 |
NCT03446339 |
Recruiting |
Pulmonary Hypertension Screening for Rheumatology Patients (SOPHIE) |
- Connective Tissue Diseases
- Systemic Sclerosis
- Systemic Lupus Erythematosus
|
|
Observational |
|
- The University of Hong Kong
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Prevalence of asymptomatic pulmonary hypertension in Chinese patients with connective tissue diseases
- Clinical predictor of Echocardiography for pulmonary hypertension in Chinese patients with connective tissue diseases
- Clinical predictor of BNP assay for pulmonary hypertension in Chinese patients with connective tissue diseases
|
1800 |
All |
18 Years and older (Adult, Senior) |
NCT03446339 |
PH_Screening_1.4.2017 ver.1 |
PAH |
August 3, 2017 |
August 2020 |
December 2020 |
February 26, 2018 |
February 26, 2018 |
|
- The University of Hong Kong
Hong Kong, China
|
129 |
NCT02920346 |
Recruiting |
Prospective Maternal Surveillance of SSA (Sjögren Syndrome A) Positive Pregnancies Using a Hand-held Fetal Heart Rate Monitor |
- Sjogren's Syndrome
- Neonatal Systemic Lupus Erythematosus
- Fetal Heart Block Complete
|
|
Observational |
|
- University of Colorado, Denver
- Children's Research Institute
- Stollery Children's Hospital
- (and 13 more...)
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Development of Fetal AV (atrio-ventricular) heart block
|
700 |
Female |
18 Years to 50 Years (Adult) |
NCT02920346 |
13-1879 |
|
April 2014 |
December 2020 |
December 2020 |
September 30, 2016 |
December 22, 2017 |
|
- Children's Hospital Colorado
Aurora, Colorado, United States
|
130 |
NCT03152058 |
Recruiting |
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy |
- High Risk Pregnancy
- Pregnancy Complications
- Antiphospholipid Syndrome in Pregnancy
- Lupus Anticoagulant Disorder
|
|
Interventional |
Phase 2 |
- Ware Branch
- Hospital for Special Surgery, New York
- University of Toronto
- (and 2 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Fetal death and/or preterm delivery (<34 weeks) due to PE or PI in women with APS and LAC
- Additional adverse outcomes or pertinent concerns, possibly related to study intervention
|
50 |
Female |
18 Years to 38 Years (Adult) |
NCT03152058 |
94818 |
|
May 17, 2017 |
May 2020 |
May 2021 |
May 12, 2017 |
November 13, 2017 |
|
- Hospital for Special Surgery
New York, New York, United States - University of Utah
Salt Lake City, Utah, United States - TRIO Advancing Reproductive Care
Toronto, Ontario, Canada
|
131 |
NCT00001979 |
Recruiting |
Immune System Related Kidney Disease |
- Glomerulonephritis
- Lupus Nephritis
- Membranous Glomerulonephritis
- (and 2 more...)
|
|
Observational |
|
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Other
|
- Study of characterization of the clinical and laboratory features of these disorders and studies of natural history, as well as evaluation of responses to standard treatment.
|
99999999 |
All |
Child, Adult, Senior |
NCT00001979 |
920156 92-DK-0156 |
|
April 14, 1992 |
|
|
January 21, 2000 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
132 |
NCT00055055 |
Recruiting |
Study of Families With Twins or Siblings Discordant for Rheumatic Disorders |
- Rheumatic Diseases
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- (and 3 more...)
|
|
Observational |
|
- National Institute of Environmental Health Sciences (NIEHS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Physician Global Assesment Questionnaire
|
1550 |
All |
Child, Adult, Senior |
NCT00055055 |
030099 03-E-0099 |
|
February 14, 2003 |
|
|
February 17, 2003 |
April 4, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States - University of Wisconsin
Madison, Wisconsin, United States
|
133 |
NCT03257878 |
Recruiting |
Health-related Quality of Life in Korean Patients With Rheumatic Diseases |
|
- Other: validated Korean version of the SF36 and EQ-5D
|
Observational |
|
- Seoul National University Hospital
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- comparison of physical component scores (PCS) of the SF 36 questionnaire between patients with systemic sclerosis and other rheumatic diseases
- comparison of mental component scores (MCS) of the SF 36 questionnaire between patients with systemic sclerosis and other rheumatic diseases
- comparison of physical functioning (PF) scores of the SF 36 questionnaire between patients with systemic sclerosis and other rheumatic diseases
- (and 8 more...)
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT03257878 |
H-1701-023-821 |
|
March 31, 2017 |
December 31, 2017 |
December 31, 2017 |
August 22, 2017 |
August 22, 2017 |
|
- Seoul National University Hospital
Seoul, Korea, Republic of
|
134 |
NCT02102594 |
Recruiting |
Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) |
- Myasthenia Gravis
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
|
|
Interventional |
Phase 2 |
- Charite University, Berlin, Germany
- Prof. Dr. med. Falk Hiepe (Charité, Internal Medicine / Rheumathology)
- NeuroCure Clinical Research Center, Charite, Berlin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- change in disease specific antibody titers after application of Bortezomib
- Change in disease specific antibody titer after Bortezomib application
- Change in quality of life (Qol score)
- (and 6 more...)
|
18 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02102594 |
TAVAB 2013-005362-19 |
TAVAB |
October 2014 |
December 2018 |
December 2018 |
April 3, 2014 |
February 2, 2018 |
|
- Charite - Universitätsmedizin Berlin, NeuroCure Clinical Research Center
Berlin, Germany - Charité - Universitätsmedizin Berlin, Internal Medicine / Rheumathology
Berlin, Germany
|
135 |
NCT03143413 |
Recruiting |
Echo Systemic Sclerosis |
- Systemic Sclerosis
- Gougerot Sjogren Syndrome
- Sicca-Asthenia-Polyalgia Syndrome
|
|
Observational |
|
- University Hospital, Clermont-Ferrand
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Jousse-Joulin ultrasonography score
- Ultrasonography score equal or higher than 2 on at least one salivary gland
- Ultrasonography score equal or higher than 3 on at least one salivary gland
- (and 2 more...)
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT03143413 |
CHU-323 2016-A01256-45 |
|
March 24, 2017 |
March 2019 |
May 2019 |
May 8, 2017 |
May 8, 2017 |
|
- CHU Clermont-Ferrand
Clermont-Ferrand, Auvergne, France
|
136 |
NCT00482794 |
Recruiting |
Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome |
- Antiphospholipid Syndrome
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Other
|
- characterize genetic risk factors associated with the development of familial antiphospholipid antibody syndrome.
|
2800 |
All |
Child, Adult, Senior |
NCT00482794 |
Pro00013845 |
APS |
June 2006 |
July 2018 |
December 2018 |
June 5, 2007 |
November 6, 2017 |
|
- Duke University Medical Center
Durham, North Carolina, United States
|
137 |
NCT01988506 |
Recruiting |
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases |
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Systemic Lupus Erythematosus
- (and 11 more...)
|
|
Interventional |
Phase 2 |
- Assistance Publique - Hôpitaux de Paris
- Iltoo Pharma
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentages of Tregs
- CRP, CRP ulta sensible, PCT, Albumin, LDH, anemia
- Number of relapses
- (and 4 more...)
|
132 |
All |
18 Years and older (Adult, Senior) |
NCT01988506 |
P130101 2013-001232-22 |
TRANSREG |
January 6, 2014 |
July 14, 2018 |
February 6, 2020 |
November 20, 2013 |
January 11, 2018 |
|
- Service d' Hépato Gastro Entérologie - Hôpital SAINT-ANTOINE
Paris, Ile De France, France - Service de Gastro Entérologie - Hôpital SAINT-ANTOINE
Paris, Ile De France, France - Service de Rhumatologie - Hôpital SAINT-ANTOINE
Paris, Ile De France, France - (and 8 more...)
|
138 |
NCT02450396 |
Recruiting |
Pregnancy and Medically Assisted Conception in Rare Diseases |
- Rheumatoid Arthritis
- Spondyloarthritis
- Psoriatic Arthritis
- (and 8 more...)
|
|
Observational |
|
- Assistance Publique - Hôpitaux de Paris
- SNFMI
- SFR
- CRAT
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- "good" obstetric outcome
- Define the best therapeutic management strategies
- Conduct pharmacoepidemiologic studies
- Analyse the frequency of exposure to various medications (immunosuppressors, biological therapy, corticosteroids) and their maternal and fetal consequences (e.g., infectious complications).
|
1000 |
Female |
Child, Adult, Senior |
NCT02450396 |
13.381bis |
EGR2 |
June 2014 |
June 2019 |
December 2019 |
May 21, 2015 |
June 24, 2016 |
|
- Hôpital Cochin
Paris, France
|
139 |
NCT03473912 |
Not yet recruiting |
Meir Medical Center Rheumatologic Biobank |
- Rheumatoid Arthritis
- Lupus Erythematosus, Systemic
- Systemic Sclerosis
- (and 2 more...)
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
500 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT03473912 |
MMC17-0116CTIL |
|
November 2018 |
November 2037 |
November 2037 |
March 22, 2018 |
March 22, 2018 |
|
|
140 |
NCT01758250 |
Recruiting |
Microvascular and Fibrosis Imaging Study |
- Autoimmune Diseases
- Sickle Cell Disease
- Chronic Graft Versus Host Disease
|
- Other: Acoustic Radiation Force Impulse (ARFI)
- Other: Laser Doppler Flowmetry (LDF)
- Other: Laser Doppler Perfusion Imaging (LDI)
- (and 3 more...)
|
Observational |
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Microvascular density in oral mucosa and skin
- Microvascular Perfusion in oral mucosa and skin
|
220 |
All |
18 Years and older (Adult, Senior) |
NCT01758250 |
Pro00039256 |
|
February 2013 |
January 2019 |
December 2019 |
January 1, 2013 |
April 5, 2018 |
|
- Duke University Medical Center
Durham, North Carolina, United States
|
141 |
NCT02747277 |
Recruiting |
Analysis of B Cells From Autoimmune Individuals |
- Lupus Erythematosus
- Rheumatoid Arthritis
- Type 1 Diabetes
|
|
Observational |
|
- University of Colorado, Denver
|
Other |
- Observational Model: Other
- Time Perspective: Cross-Sectional
|
- Frequency of kappa to lambda ratios of B cells in blood of autoimmune adults
- Frequency of CD19 and IgM low B cells in cord blood of babies born from autoimmune mothers
|
200 |
All |
18 Years to 65 Years (Adult) |
NCT02747277 |
16-0541 UL1TR001082 |
|
May 2016 |
May 2024 |
May 2026 |
April 21, 2016 |
June 16, 2017 |
|
- University of Colorado
Aurora, Colorado, United States
|
142 |
NCT02466217 |
Recruiting |
Phenomics in Autoimmune and Inflammatory Diseases |
- Healthy Volunteer
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- (and 10 more...)
|
- Other: 1: AID groups
- Other: 2: Control groups
|
Observational |
|
- Assistance Publique - Hôpitaux de Paris
- National Research Agency, France
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Total peripheral blood gene expression between patients, expressed as fluorescence intensity
- Tregs and Tconvs T cell receptor repertoire, expressed as the % of unique TCR sequences
- HLA type and SNPs expressed as the occurrence events across patients
- (and 15 more...)
|
1300 |
All |
18 Years and older (Adult, Senior) |
NCT02466217 |
P141006 2015-A00558-41 |
TRANSIMMUNOM |
July 2015 |
July 2019 |
July 2021 |
June 9, 2015 |
December 13, 2016 |
|
- Rhumatologie - Hôpital Saint-Antoine
Paris, France - CIC Paris-Est, Hôpital PITIE SALPETRIERE
Paris, France
|
143 |
NCT03239470 |
Recruiting |
Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus |
- Pemphigus Foliaceus
- Pemphigus Vulgaris
|
- Biological: Cohort 1: 2.5 x 10^8 PolyTregs
- Biological: Cohort 2: 10x10^8 PolyTregs
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- Autoimmunity Centers of Excellence
|
NIH / Other |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Significant Events as Defined by Grade 3 or higher adverse event(s) by Week 52
|
12 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03239470 |
DAIT APG01 APG01 |
|
September 22, 2017 |
September 2020 |
September 2020 |
August 4, 2017 |
April 10, 2018 |
|
- University of California San Francisco School of Medicine: Department of Dermatology
San Francisco, California, United States - University of Iowa Health Care: Department of Dermatology
Iowa City, Iowa, United States - Duke University Medical Center: Department of Dermatology
Durham, North Carolina, United States - University of Texas Southwestern Medical Center: Department of Dermatology
Dallas, Texas, United States
|
144 |
NCT03505840 |
Not yet recruiting New |
The Value of Placental Vascularization and Placental Volume in Pregnancy |
- Antiphospholipid Syndrome in Pregnancy
|
- Diagnostic Test: Ultrasound with Doppler and 3D technology
|
Observational |
|
- Aljazeera Hospital
- Cairo University
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The number of participants who will have impaired placental doppler indices
|
100 |
Female |
18 Years to 40 Years (Adult) |
NCT03505840 |
vocal in placenta |
|
April 21, 2018 |
January 1, 2019 |
January 10, 2019 |
April 23, 2018 |
April 23, 2018 |
|
|
145 |
NCT03229746 |
Not yet recruiting |
Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia |
|
- Drug: Hydroxychloroquine
- Drug: vincristine
- Drug: azathioprine
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Platelet count
- side effects
- anti- nuclear antibodies role
- (and 2 more...)
|
40 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03229746 |
17200058 |
|
August 1, 2017 |
March 1, 2018 |
April 1, 2018 |
July 26, 2017 |
July 26, 2017 |
|
|
146 |
NCT02333890 |
Recruiting |
A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer |
- Breast Cancer
- Invasive Breast Cancer
|
- Drug: Chloroquine
- Drug: Placebo
|
Interventional |
Phase 2 |
- Ottawa Hospital Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Effect of a brief course of CQ on tumour proliferation and apoptosis
- Measure of Circulating CQ Metabolites
- Autophagic Markers in Cancerous and Stromal Tissue
|
60 |
Female |
18 Years and older (Adult, Senior) |
NCT02333890 |
OTT 14-02 |
CUBiC |
July 2015 |
March 2017 |
March 2018 |
January 7, 2015 |
November 18, 2016 |
|
- The Ottawa Hospital Woman's Breast Health Centre
Ottawa, Ontario, Canada
|
147 |
NCT02892630 |
Recruiting |
Immune Thrombocytopenia in Pregnancy |
- Immune Thrombocytopenia
- Pregnancy
|
|
Observational |
|
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Composite criteria including in the two principal groups (pregnant and none pregnant) : Frequency of: - ITP treatment modification,- biologic worsening and severe thrombocytopenia (<30G/L), - hemorrhagic complication and ITP status modification
- Identification of risk factors of ITP worsening during pregnancy
- Evaluation of obstetrical complications in case of ITP
- (and 3 more...)
|
300 |
Female |
18 Years and older (Adult, Senior) |
NCT02892630 |
AOM12204 |
TIGRO |
February 3, 2014 |
May 2019 |
May 2019 |
September 8, 2016 |
October 19, 2017 |
|
- Henri Mondor Hospital
Creteil, France
|
148 |
NCT02828670 |
Recruiting |
Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA) |
- Autoimmune Hemolytic Anemia
|
- Biological: blood sample
- Procedure: spleen sample
|
Observational |
|
- Centre Hospitalier Universitaire Dijon
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- the proportion of circulating T follicular helper lymphocytes (TFH) in patients with Autoimmune Hemolytic Anemia (AIHA) and in control subjects.
- the proportion of circulating TFH in patients with Autoimmune Hemolytic Anemia (AIHA), at diagnosis and after 3 months of treatment with steroids
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02828670 |
AUDIA APJ 2014 |
TFH and AIHA |
June 7, 2016 |
June 2018 |
June 2019 |
July 11, 2016 |
March 13, 2018 |
|
- CHU Dijon Bourgogne
Dijon, France
|
149 |
NCT02910076 |
Not yet recruiting |
The Influence of Plaquenil/Hydroxychloroquine (HCQ) on Insulin Secretion |
|
|
Interventional |
Phase 1 Phase 2 |
- Hadassah Medical Organization
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
40 |
Male |
18 Years to 60 Years (Adult) |
NCT02910076 |
0059-16-HMO-CTIL |
|
October 2016 |
August 2018 |
|
September 21, 2016 |
September 21, 2016 |
|
|
150 |
NCT02821572 |
Recruiting |
Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP) |
|
- Biological: blood sample
- Procedure: spleen sample
|
Observational |
|
- Centre Hospitalier Universitaire Dijon
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- 1. The expressions of the activating FcγRs and the inhibiting receptor (FcγRIIb) on monocytes will be compared between ITP patients at diagnosis and controls - physiological parameter
- 1. The expressions of the activating FcγRs and the inhibiting receptor (FcγRIIb) on splenic macrophages will be compared between ITP patients and controls. - physiological parameter
|
70 |
All |
18 Years and older (Adult, Senior) |
NCT02821572 |
BONNOTTE PARI 2013 |
PTI Fc |
October 2, 2014 |
October 2018 |
October 2020 |
July 1, 2016 |
March 9, 2018 |
|
- CHU Dijon Bourgogne
Dijon, France
|